340B Myths vs Facts
Separating fact from fiction with data, research, and evidence. Addressing common pharmaceutical manufacturer arguments against the 340B program.
Common Myths Debunked
Pharmaceutical manufacturers make several recurring claims about the 340B program. Here's what the evidence actually shows.
Fact
340B hospitals provide $13.9M in average annual uncompensated care vs. $4.1M for non-340B hospitals—nearly 3x more free care
Evidence: Federal law requires 340B savings benefit eligible patients. HRSA audits ensure compliance with severe penalties for misuse.
Fact
Eligibility criteria are set by federal statute, not administrative discretion—growth reflects increased need for safety-net services
Evidence: Between 2010-2020, uninsured Americans ranged from 28-49M while drug spending increased 34%, driving legitimate program growth.
Fact
Contract pharmacies are explicitly authorized by HRSA and essential for rural hospitals and FQHCs lacking pharmacy infrastructure
Evidence: 30% of covered entities lack in-house pharmacies; for rural hospitals this exceeds 50%. Manufacturer restrictions harm patients.
Fact
340B represents <2% of the U.S. drug market; pharmaceutical industry maintains 15-20% profit margins—highest of any sector
Evidence: Top 10 pharma companies: $500B+ annual revenue, $100B+ returned to shareholders. 340B doesn't threaten innovation.
Fact
68% of 340B hospitals publish annual community benefit reports; nonprofits report on IRS Form 990; HRSA conducts regular audits
Evidence: Covered entities document billions in uncompensated care, charity care, and community programs funded by 340B.
Fact
340B funds medication assistance programs, charity care, and expanded services for patients who can't afford to pay anything
Evidence: Point-of-sale discounts only help those who can pay something; 340B model serves those with greatest need.
By the Numbers: 340B vs Non-340B Hospitals
Data demonstrates the program's measurable community impact
vs. 23% of non-340B hospitals
vs. 34% of non-340B hospitals
vs. 52% of non-340B hospitals
Federal law requires that 340B savings benefit eligible patients and expand comprehensive services
340B hospitals provide 240% more uncompensated care than non-participating hospitals
The program represents less than 2% of the pharmaceutical market while industry maintains record profits
340B hospitals are significantly more likely to offer specialized services for vulnerable populations
Patient-Focused Talking Points
Compelling, evidence-based messages for media interviews, stakeholder communications, and advocacy efforts. Always lead with patient impact.
"The 340B program helps us provide free or reduced-cost medications to patients who are uninsured, underinsured, or struggling to afford their prescriptions. Without 340B, many of our patients would have to choose between filling their prescriptions and paying for groceries or rent."
"The $100 billion in annual community benefits generated by 340B doesn't just help individual patients—it strengthens entire communities. At our facility, 340B savings fund our mobile health clinic, mental health services, transportation assistance, and extended evening and weekend hours."
"340B enables us to serve the patients who fall through the cracks: the working poor who earn too much for Medicaid but can't afford marketplace insurance, rural residents with no nearby healthcare options, patients battling chronic diseases who need ongoing support."
"When pharmaceutical manufacturers restrict 340B, they're not hurting hospitals—they're hurting patients. Every dollar we lose in 340B savings is a dollar we can't spend on patient assistance programs, charity care, or community health services."
Lead with patients, not program mechanics: Start every answer with patient impact before explaining how 340B works
Use local data and stories: Personalize these talking points with your facility's specific numbers and patient examples
Bridge back to core message: No matter what question is asked, find a way to return to one of these patient-focused points
Humanize with examples: Have 2-3 specific (anonymized) patient stories ready that illustrate each talking point
Learn More About 340B's Impact
Explore additional resources, patient stories, and advocacy tools to understand and defend this vital program.